Shire Recognizes Rare Disease Day 2014

                    Shire Recognizes Rare Disease Day 2014

  PR Newswire

  LEXINGTON, Massachusetts, February 28, 2014

LEXINGTON, Massachusetts, February 28, 2014 /PRNewswire/ --

Global Initiatives Underscore Shire's Long-term Commitment to the Rare Disease
Community

Shire plc (LSE: SHP, NASDAQ: SHPG) today announced its support of Rare Disease
Day and invites others to join them in its continued commitment to the rare
disease community. Observed annually on the last day of February, Rare Disease
Day is coordinated at the international level by the European Organisation for
Rare Diseases (EURORDIS) and by National Alliances and Patient Organizations
at the national level.

There are estimated to be between 6,000 and 8,000 rare diseases worldwide. ^[
^1 ^] These diseases affect nearly 30 million people in the US and
approximately 30 million people in Europe. ^[ ^1 ^] ^, ^[ ^2 ^] A disease or
disorder is classified as rare in Europe when it affects less than 1 in 2,000
people and in the U.S. when it affects fewer than 200,000 people. ^[ ^1 ^] ^,
^[ ^3 ^] It is estimated that 75 percent of rare diseases affect children, and
30 percent of rare disease patients will die before the age of 5. ^[ ^1 ^]

The theme for this year's Rare Disease Day, "Join Together for Better Care",
encourages everyone supporting the rare disease community to find ways to work
together to help both patients and their families find common solutions for
care and remind them they are not alone. Rare disease care has many facets and
is a universal need, and only through joining together will we find ways to
provide the different kinds of care that people living with rare diseases need
to improve their lives.

"On this important day, we show our commitment to the rare disease community
by joining forces to raise awareness of rare diseases worldwide," said Jeff
Poulton, Head of the Rare Disease Business Unit at Shire. "Shire's purpose is
to enable people with life-altering conditions to lead better lives and so we
support the efforts of Rare Disease Day to better patient care. We hope that
by working together we can help ensure patients with rare diseases receive
consistent, reliable and effective treatments and services to meet their
individual needs."

Shire is sponsoring and participating in a variety of Rare Disease Day
activities, and partnering with local patient organizations around the world,
to help educate physicians and communities about rare diseases and advocate
for those whose lives are impacted. Some of these initiatives include:

  *The Global Genes Project with Wear That You Care™ to raise awareness of
    rare genetic disorders;
  *EURORDIS Roundtable of Companies on the topic of "Unlocking Europe's
    Potential in Rare Disease Therapies" on February 26 in Brussels, Belgium;
  *Rare Disease Day Legislative Advocates (RDLA) "Rare Disease Day
    Legislative Conference and Lobby Day" from February 25-27 ^th in
    Washington DC, US;
  *Spanish Federation of Rare Diseases (FEDER) experts meeting on February 21
    ^st and the official Rare Disease Day event on February 28 ^th in Madrid,
    Spain;
  *Lysosomal Storage Disease Department at the Queen Elizabeth Hospital in
    Birmingham, UK, rare disease event;
  *The 2 ^nd National Editorial Award on Rare Disease and Rare Cancers
    organized by OMAR (Observatory Rare Disease) in Italy;
  *Rare Voices Australia (RVA) to hold a Rare Disease Day meeting, in
    partnership with Wesley Hospital, in Brisbane, and assisting RVA in
    holding a Friends of Rare Disease Parliamentary event at Parliament House
    in Canberra;
  *Rare Disease Day activities organized by the non-profit organization
    Promotion of Research on Intellectual Property (PRIP) Tokyo in Japan;
  *Argentinean Federation of Rare Diseases (FADEPOF) awareness campaign
    "Descubrinos, estamos acá" ("Discover us, we are here") and activities for
    Rare Disease Day.

As a leader in rare diseases, Shire has a global focus on the research,
development, registration and marketing of therapies for the treatment rare
conditions.

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty
medicines to meet significant unmet patient needs.

We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal and
Internal Medicine and we are developing treatments for symptomatic conditions
treated by specialist physicians in other targeted therapeutic areas.

http://www.shire.com

FORWARD - LOOKING STATEMENTS - "SAFE HARBOR" STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995

Statements included in this announcement that are not historical facts are
forward-looking statements. Forward-looking statements involve a number of
risks and uncertainties and are subject to change at any time. In the event
such risks or uncertainties materialize, Shire's results could be materially
adversely affected. The risks and uncertainties include, but are not limited
to, that:

  *Shire's products may not be a commercial success;
  *revenues from ADDERALL XR are subject to generic erosion and revenues from
    INTUNIV will become subject to generic competition starting in December
    2014;
  *the failure to obtain and maintain reimbursement, or an adequate level of
    reimbursement, by third-party payors in a timely manner for Shire's
    products may impact future revenues, financial condition and results of
    operations;
  *Shire conducts its own manufacturing operations for certain of its Rare
    Diseases products and is reliant on third party contractors to manufacture
    other products and to provide goods and services. Some of Shire's products
    or ingredients are only available from a single approved source for
    manufacture. Any disruption to the supply chain for any of Shire's
    products may result in Shire being unable to continue marketing or
    developing a product or may result in Shire being unable to do so on a
    commercially viable basis for some period of time.
  *the development, approval and manufacturing of Shire's products is subject
    to extensive oversight by various regulatory agencies and regulatory
    approvals or interventions associated with changes to manufacturing sites,
    ingredients or manufacturing processes could lead to significant delays,
    increase in operating costs, lost product sales, an interruption of
    research activities or the delay of new product launches;
  *the actions of certain customers could affect Shire 's ability to sell or
    market products profitably. Fluctuations in buying or distribution
    patterns by such customers can adversely impact Shire's revenues,
    financial conditions or results of operations;
  *investigations or enforcement action by regulatory authorities or law
    enforcement agencies relating to Shire's activities in the highly
    regulated markets in which it operates may result in the distraction of
    senior management, significant legal costs and the payment of substantial
    compensation or fines;
  *adverse outcomes in legal matters and other disputes, including Shire's
    ability to enforce and defend patents and other intellectual property
    rights required for its business, could have a material adverse effect on
    Shire's revenues, financial condition or results of operations;
  *Shire faces intense competition for highly qualified personnel from other
    companies, academic institutions, government entities and other
    organizations. Shire is undergoing a corporate reorganization and the
    consequent uncertainty could adversely impact Shire's ability to attract
    and/or retain the highly skilled personnel needed for Shire to meet its
    strategic objectives;
  *failure to achieve Shire's strategic objectives with respect to the
    acquisition of ViroPharma Incorporated may adversely affect Shire's
    financial condition and results of operations;

and other risks and uncertainties detailed from time to time in Shire's
filings with the U.S. Securities and Exchange Commission, including its most
recent Annual Report on Form 10-K.

References

1.EURORDIS. What is a rare disease? Factsheet. Available at:
    http://www.eurordis.org/sites/default/files/publications/Fact_Sheet_RD.pdf
    . Last accessed February 2014.
2.NORD. Available at: http://www.rarediseases.org/about
3.National Institutes of Health. FAQ about rare diseases. Available at:
    http://www.ncats.nih.gov/about/faq/rare/rare-faq.html . Last accessed
    February 2014.

For further information please contact: Media Lauren O'Brien lobrien@shire.com
+41-22-419-4040

Gwen Fisher gfisher@shire.com +1-484-595-9836
 
Press spacebar to pause and continue. Press esc to stop.